David W Griggs

Ballwin, MO, United States of America

David W Griggs

USPTO Granted Patents = 8 

 

Average Co-Inventor Count = 3.1

ph-index = 3

Forward Citations = 37(Granted Patents)


Company Filing History:


Years Active: 2008-2022

Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: The Innovative Journey of David W Griggs: Pioneering Integrin Antagonists

Introduction:

David W Griggs, an esteemed inventor based in Ballwin, MO, has made significant contributions to the field of pharmaceuticals with his groundbreaking patents. With a total of 8 patents to his name, Griggs has been a driving force in developing integrin antagonists for various medical applications.

Latest Patents:

Griggs' recent patents include Integrin Antagonists and Meta-azacyclic Amino Benzoic Acid Derivatives as Pan Integrin Antagonists. These pharmaceutical agents have shown promising results in inhibiting or antagonizing integrins ανβ1 and/or α5β1, offering new possibilities for treating a range of diseases and disorders.

Career Highlights:

Having worked at renowned institutions such as Saint Louis University and Agouron Pharmaceuticals, Inc., Griggs has honed his expertise in the pharmaceutical industry. His innovative spirit and dedication have led to the successful development of cutting-edge medical solutions.

Collaborations:

Throughout his career, Griggs has collaborated with esteemed professionals in the field, including Peter G Ruminski and Christopher Todd Bauer. Together, they have pushed the boundaries of pharmaceutical research, paving the way for new advancements in integrin-targeted therapies.

Conclusion:

David W Griggs' pioneering work in developing integrin antagonists underscores his passion for innovation and commitment to improving healthcare. His patents stand as a testament to his contributions to the field, shaping the future of pharmaceuticals and offering hope for transformative medical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…